Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Single-cell analysis of the epigenomic and transcriptional landscape of innate immunity to seasonal and adjuvanted pandemic influenza vaccination in humans

ABSTRACT: This SuperSeries is composed of the SubSeries listed below.

ORGANISM(S): Homo sapiens

PROVIDER: GSE165907 | GEO | 2021/06/25

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Single-cell analysis of the epigenomic and transcriptional landscape of innate immunity to seasonal and adjuvanted pandemic influenza vaccination in humans

Project description:Human subjects were vaccinated with seasonal influenza vaccine at day 0 (TIV, 2014-2015). A subgroup of subjects (abx) received an additional oral antibiotic regimen, consisting of neomycin, vancomycin, and metronidazole, between days -3 and 1. CD14+ monocytes were isolated from PBMCs of vaccinated subjects (2 antibiotic treated, 3 controls) at day 0 and 30 using FACS. RNA-seq was used to analyze the transcriptional landscape in these cells.

2021-06-25 | GSE166063 | GEO

Single-cell analysis of the epigenomic and transcriptional landscape of innate immunity to seasonal and adjuvanted pandemic influenza vaccination in humans [ATAC-seq]

Project description:Human subjects were vaccinated with seasonal influenza vaccine at day 0 (TIV, 2014-2015). A subgroup of subjects (abx) received an additional oral antibiotic regimen, consisting of neomycin, vancomycin, and metronidazole, between days -3 and 1. CD14+ monocytes, mDCs, and pDCs were isolated from PBMCs of vaccinated subjects (3 antibiotic treated, 5 controls) at day -21 (BL), 0 and 30 using FACS. ATAC-seq was used to analyze the chromatin accessibility landscape in these cells.

2021-06-25 | GSE166180 | GEO

Single-cell analysis of the epigenomic and transcriptional landscape of innate immunity to seasonal and adjuvanted pandemic influenza vaccination in humans (H5N1_scRNA-seq)

Project description:Human subjects were vaccinated with adjuvanted (AS03) or unadjuvanted pre-pandemic influenza vaccines H5N1 at day 0 and d21. We then used scRNA-seq to construct the single-cell landscape of the innate immune response to those vaccines at the transcriptional level. PBMCs from vaccinated individuals were isolated at day 0, 21, and 42, then enriched for DC subsets using flow cytometry and analyzed using droplet-based single-cell gene expression profiling.

2021-06-25 | GSE165903 | GEO

Single-cell analysis of the epigenomic and transcriptional landscape of innate immunity to seasonal and adjuvanted pandemic influenza vaccination in humans (TIV_scATAC-seq)

Project description:Human subjects were vaccinated with seasonal influenza vaccine (TIV, 2014-2015). We then used scATAC-seq to construct the single-cell landscape of the innate immune response to TIV at the epigenomic level. PBMCs from vaccinated individuals were isolated at day 0, 1, and 30, then enriched for DC subsets using flow cytometry and analyzed using droplet-based single-cell chromatin accessibility profiling.

2021-06-25 | GSE165906 | GEO

Single-cell analysis of the epigenomic and transcriptional landscape of innate immunity to seasonal and adjuvanted pandemic influenza vaccination in humans (TIV_scRNA-seq)

Project description:Human subjects were vaccinated with seasonal influenza vaccine (TIV, 2014-2015). We then used scRNA-seq to constructed the single-cell landscape of the innate immune response to TIV at the transcriptional level. PBMCs from vaccinated individuals were isolated at day 0, 1, and 30, then enriched for DC subsets using flow cytometry and analyzed using droplet-based single-cell gene expression profiling.

2021-06-25 | GSE165905 | GEO

Single-cell analysis of the epigenomic and transcriptional landscape of innate immunity to seasonal and adjuvanted pandemic influenza vaccination in humans (H5N1_scATAC-seq)

Project description:Human subjects were vaccinated with adjuvanted (AS03) or unadjuvanted pre-pandemic influenza vaccines H5N1 at day 0 and d21. We then used scATAC-seq to construct the single-cell landscape of the innate immune response to those vaccines at the epigenomic level. PBMCs from vaccinated individuals were isolated at day 0, 21, and 42, then enriched for DC subsets using flow cytometry and analyzed using droplet-based single-cell chromatin accessibility profiling.

2021-06-25 | GSE165904 | GEO

Single-cell analysis of the epigenomic and transcriptional landscape of innate immunity to seasonal and adjuvanted pandemic influenza vaccination in humans

Project description:Single-cell analysis of the epigenomic and transcriptional landscape of innate immunity to seasonal and adjuvanted pandemic influenza vaccination in humans

| PRJNA699168 | ENA

Single-cell analysis of the epigenomic and transcriptional landscape of innate immunity to seasonal and adjuvanted pandemic influenza vaccination in humans

Project description:Single-cell analysis of the epigenomic and transcriptional landscape of innate immunity to seasonal and adjuvanted pandemic influenza vaccination in humans

| PRJNA698558 | ENA

MF59-adjuvanted vaccines for seasonal and pandemic influenza prophylaxis.

Project description:Influenza is a major cause of worldwide morbidity and mortality through frequent seasonal epidemics and infrequent pandemics. Morbidity and mortality rates from seasonal influenza are highest in the most frail, such as the elderly, those with underlying chronic conditions and very young children. Antigenic mismatch between strains recommended for vaccine formulation and circulating viruses can further reduce vaccine efficacy in these populations. Seasonal influenza vaccines with enhanced, cross-reactive immunogenicity are needed to address these problems and can confer a better immune protection, particularly in seasons were antigenic mismatch occurs. A related issue for vaccine development is the growing threat of pandemic influenza caused by H5N1 avian strains. Vaccines against strains with pandemic potential offer the best approach for reducing the potential impact of a pandemic. However, current non-adjuvanted pre-pandemic vaccines offer suboptimal immunogenicity against H5N1. For both seasonal and pre-pandemic vaccines, the addition of adjuvants may be the best approach for providing enhanced cross-reactive immunogenicity. MF59, the first oil-in-water emulsion licensed as an adjuvant for human use, can enhance vaccine immune responses through multiple mechanisms. A trivalent MF59-adjuvanted seasonal influenza vaccine (Fluad has shown to induce significantly higher immune responses to influenza vaccination in the elderly, compared with non-adjuvanted vaccines, and to provide cross-reactive immunity against divergent influenza strains. Similar results have been generated with a MF59-adjuvanted H5N1 pre-pandemic vaccine, which showed higher and broader immunogenicity compared with non-adjuvanted pre-pandemic vaccines.

| S-EPMC4634121 | biostudies-other

Single-cell analysis of the epigenomic and transcriptional landscape of innate immunity to seasonal and adjuvanted pandemic influenza vaccination in humans (H5N1_scRNA-seq)

Project description:Single-cell analysis of the epigenomic and transcriptional landscape of innate immunity to seasonal and adjuvanted pandemic influenza vaccination in humans (H5N1_scRNA-seq)

| PRJNA698740 | ENA

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data